# A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes

> **NCT03298542** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 8 (actual)

## Conditions studied

- Pre-Symptomatic Type 1 Diabetes

## Interventions

- **DRUG:** Golimumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03298542
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-16
- **Primary completion:** 2020-12-21
- **Final completion:** 2021-06-01
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03298542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03298542, "A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03298542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*